[Epidemiology and clinical course in hepatitis C-positive patients treated with dialysis in Piemonte. Work group of the RPDT].
The high prevalence of HCV positivity in dialysis patients has recently prompted several studies on this controversial subject. The aim of the study was an evaluation of HCV positivity and of influence on clinical outcome in 2,404 patients on dialysis in Piedmont (Northern Italy Region, about 4,400,000 inhab., 20 Dialysis Centers) at December 1993 (32.7% HCV-positive according to the Regional Registry of Dialysis and Transplantation). As expected, a strong correlation was found with time on dialysis (94.4% in patients with treatment follow-up > or = 20 years) and blood transfusions (41.3% HCV positivity in transfused patients versus 22.6% in not transfused ones; p < 0.0001). Dialysis in a hospital setting is confirmed as at high risk of infection, since HCV positivity was 19.6% in patients always treated by bicarbonate dialysis in hospital versus 8.9% in those treated only by CAPD (start of dialysis in 1992-1993). Despite the high prevalence of HCV positivity, however, death rates for liver disease and for all gastrointestinal causes are very low, regardless of HCV antibody status (1.2% in HCV positive versus 2.3% in HCV negative, NS). Whether this depends upon different clinical features of HCV infection in dialysis patients or merely deflects a relatively short follow-up will be matter of discussion in the future.
Pellerey
M
M
Servizio di Nefrologia e Dialisi, Ospedale degli Infermi, Biella. Servizio de Nefrologia e Dialisi, Ospedale degli Infermia, Biella.
Bergia
R
R
Berto
I M
IM
Caramello
E
E
Cravero
R
R
Dionisio
P
P
Stramignoni
E
E
Valenti
M
M
Piccoli
G B
GB
Salomone
M
M
Bajardi
P
P
D000328:Adult; D002423:Cause of Death; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000097:blood / Q000453:epidemiology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008875:Middle Aged; D015995:Prevalence; D006435:Renal Dialysis / Q000401:mortality; D016036:Seroepidemiologic Studies
D018937:Hepatitis C Antibodies